# This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.

Source: https://onco.cc/trials/nct07797907/  
OnCo record `nct07797907` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BD200 run by Biolojic Design Ltd., not yet recruiting.

## Summary

This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer. is a phase 1 interventional study registered as NCT07797907 by Biolojic Design Ltd., with 110 participants planned, started 2026-12-31. Conditions recorded: Solid Tumor (Phase I). Interventions recorded: BD200 and BD200.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07797907
- Phase: 1
- Setting: A Phase 1a/b, First-in-Human Dose Escalation and Dose Expansion Clinical Study of the Dual Targeting Trop-2 and Nectin-4 Multibody Drug Conjugate BD200 in Participants With Select Unresectable Locally Advanced or Metastatic Cancers
- Sponsor: Biolojic Design Ltd.
- Enrolled: 110

## Sources

- ClinicalTrials.gov NCT07797907: https://clinicaltrials.gov/study/NCT07797907

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [BD200](https://onco.cc/drugs/bd200/)
- companies: [Biolojic Design](https://onco.cc/companies/biolojic-design/)

---
JSON: https://onco.cc/api/v1/entities/nct07797907.json